Stage II HER2-Positive Breast Cancer: María's Survivor Story

Patient Info: María Ángeles, Female | Stage II

Biomarkers: HER2-positive

As of March 2022, María Ángeles was 4 years from diagnosis after completing 14 chemotherapy sessions, mastectomy with immediate reconstruction, 21 radiation sessions, and trastuzumab for Stage II HER2-positive breast cancer.

Invasive Lobular Carcinoma: Stephanie's Patient Story

Patient Info: Stephanie, Female, 60s

As of February 2022, Stephanie was living with locoregional recurrent ILC after extensive surgery and ongoing treatment with Ibrance/Femara, with recent bone, abdomen, and chest scans showing no new cancer growth and continued Femara without chemotherapy.

Lobular Breast Cancer AllianceRead more →

Stage III Breast Cancer: Edith's Patient Story

Patient Info: Edith | Stage III

Edith said her breast cancer was in remission while she continued hormone therapy; she had also begun separate treatment for lymphoma.

Our Cancer StoriesRead more →

Breast Cancer: Siti's Patient Story

Patient Info: Siti

Siti is recovering after treatment for a second breast cancer in the same breast and remains concerned about another recurrence.

Our Cancer StoriesRead more →

Stage III Breast Cancer: Yurley's Survivor Story

Patient Info: Yurley, Under 40 | Stage III

She reports that her breast cancer is in remission and that she continues hormone therapy.

Our Cancer StoriesRead more →

Stage III Breast Cancer: Ada's Survivor Story

Patient Info: Ada, Female, 50s | Stage III

Ada described herself as being in remission while continuing hormone therapy. Fear of relapse remained, but she was focusing on travel, healthier routines and time with loved ones.

Our Cancer StoriesRead more →

Stage II Breast Cancer: April's Survivor Story

Patient Info: April, Female, Under 40 | Stage II

April described herself as being in remission in 2024 while continuing hormone therapy and targeted therapy. Emotional and financial effects remained nearly 2 years after diagnosis.

Our Cancer StoriesRead more →

Stage IV Breast Cancer: Màrius's Patient Story

Patient Info: Màrius, Male | Stage IV

Metastatic Site: Bone: vertebra/cervical spine and ribs

As of October 2021, Màrius was living with metastatic male breast cancer described as dormant on lifelong medication after chemotherapy, radiation, 3 operations, and cyclin-inhibitor treatment.

Stage IV Invasive Lobular Carcinoma: Carol's Survivor Story

Patient Info: Carol, Female, 60s | Stage IV

Metastatic Site: Bone

Carol had de novo Stage IV breast cancer with bone metastases, achieved complete remission after chemotherapy, stayed on daily Letrozole for 10 years, then returned to NED/no active disease after Kisqali and Faslodex for bone progression.

Lobular Breast Cancer AllianceRead more →

HER2-positive left breast cancer treated with trastuzumab and mastectomy

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Biomarkers: ER-negative; PR-negative; HER2/CerbB2 strongly positive; BRCA1/2 negative for known pathogenic variants; FANCA variant of uncertain significance.

She remained alive, asymptomatic, and disease-free while undergoing annual surveillance after treatment for the left HER2-positive breast cancer.

PubMed CentralRead more →

Recovery from severe bowel and oesophageal complications after breast cancer chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: HER2-positive.

She regained independence after an 89-day hospital course, but breast surgery remained deferred three months after intensive-care discharge and tamoxifen was being used during recovery.

PubMed CentralRead more →

A durable response to trastuzumab in heavily pretreated metastatic breast cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Initial tumor ER-positive and PR-positive. Metastatic liver biopsy ER-negative and PR-negative with HER2 IHC 1+ and nonamplified. Later biopsy ER and PR weakly positive at 5%–10%, HER2 IHC 1+ and nonamplified, and ERBB3 p. with evidence of HER2/HER3 pathway activation.

Metastatic Site: lungs; hilar and mediastinal lymph nodes; liver; bone

She had ongoing benefit for more than 10 months on trastuzumab and capecitabine, with improved symptoms, lower tumor markers, and a confirmed partial response.

PubMed CentralRead more →

Stage III Breast Cancer: Onagh's Survivor Story

Patient Info: Onagh, Female | Stage III

Her stage 3 breast cancer was in complete remission, and she no longer required treatment.

Our Cancer StoriesRead more →

Stage III Breast Cancer: Beth's Survivor Story

Patient Info: Beth, Female, 40s | Stage III

As of 2021, Beth was in remission and no longer taking cancer medication after mastectomy, lymphadenectomy, chemotherapy, radiation therapy, and targeted therapy.

Our Cancer StoriesRead more →

Stage I HER2-Positive Breast Cancer: Betty's Survivor Story

Patient Info: Betty, Female, 50s | Stage I

Biomarkers: HER2-positive

As of 2021, Betty was in remission after mastectomy and chemotherapy with Herceptin, while managing side effects such as hair loss, peripheral neuropathy, and weight changes.

Our Cancer StoriesRead more →

Stage II Breast Cancer: Erika's Patient Story

Patient Info: Erika, Female, 40s | Stage II

As of 2021, Erika was undergoing treatment for Stage II breast cancer and was on targeted therapy after mastectomy, lymphadenectomy, chemotherapy, and targeted therapy.

Our Cancer StoriesRead more →

Stage II HR-Positive Breast Cancer: Faith's Survivor Story

Patient Info: Faith, Female, Under 40 | Stage II

Biomarkers: ER-positive; HER2-positive

Faith moved into survivorship after treatment for Stage II ER-positive, HER2-positive breast cancer, with ongoing fear of recurrence but renewed focus on family, nutrition, exercise, and work.

Our Cancer StoriesRead more →

Stage II Breast Cancer: Hwee's Patient Story

Patient Info: Hwee Lin, Female, 60s | Stage II

Hwee Lin was receiving targeted therapy for Stage II breast cancer and described the treatment as effective while managing fatigue, hair loss, nausea, and vomiting with medication and improved nutrition.

Our Cancer StoriesRead more →

Stage II HER2-Positive Breast Cancer: Kelsey's Survivor Story

Patient Info: Kelsey, Female, 40s | Stage II

Biomarkers: HER2-positive

Kelsey survived Stage II HER2-positive breast cancer after mastectomy, chemotherapy, and targeted therapy, with recovery supported by nutrition changes, massages, supplements, and support-group connection.

Our Cancer StoriesRead more →

Occult lobular breast cancer first discovered through colon metastases

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: ER-positive; PR-negative; HER2-negative; E-cadherin-negative

Metastatic Site: colon

Her tumour marker decreased during letrozole and palbociclib treatment, but recurrent infections interrupted therapy, and she died from urosepsis 2 years after diagnosis.

PubMed CentralRead more →

HER2-positive breast cancer diagnosed during pregnancy and later spread to bone and brain

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: Initial tumour: ER 0%, PR <1%, HER2 3+

Metastatic Site: bone (L3)|brain

After treatment and surveillance without new lesions, she developed a large symptomatic occipital brain metastasis 14 months after completing paclitaxel and radiation and died after rapid neurological deterioration.

PubMed CentralRead more →

Stage IV Breast Cancer: Pam's Patient Story

Patient Info: Pam Benchley, Female, 50s | Stage IV

Biomarkers: Not explicitly reported; treated with anti-estrogen therapy and a CDK4/6 inhibitor

Metastatic Site: Liver

As of October 2020, Pam had responded favorably to anti-estrogen therapy plus a CDK4/6 inhibitor, surgery, radiation and liver radiofrequency ablation; her oncologist described her as free of evidence of active cancer, while avoiding the term cancer-free for metastatic disease.

Cleveland ClinicRead more →

HER2-Positive Breast Cancer Linked to a Rare Immune-Related Neurological Syndrome

Patient Info: Anonymized, Female, 40s

Biomarkers: HER2-positive in both foci; one focus ER-negative/PR-positive with Ki-67 45%; second focus ER-negative/PR-negative with Ki-67 35%; anti-Yo antibodies positive in serum and CSF; tumour-susceptibility gene panel negative

At 1 year, she had completed trastuzumab, continued tamoxifen, and had no evidence of recurrent breast cancer; intensive rehabilitation improved her mobility, although balance and right-sided neurological deficits persisted.

PubMed CentralRead more →

Heart Failure and Electrical Conduction Changes During Trastuzumab Treatment

Patient Info: Anonymized, Female, 70+

Biomarkers: HER2-positive; ER-positive

Trastuzumab was suspended after acute heart failure and electrical conduction abnormalities; 4 weeks later, left ventricular function recovered and the ECG returned to normal during cardio-oncology follow-up.

PubMed CentralRead more →